BD Launches Urine Complete Cup Kit for Smarter Testing & Accuracy

BDX launches a three-tube urine collection kit to expand testing from one sample, aiming to boost lab efficiency and reduce contamination risks.

Zacks Investment Research • 10 hours ago

BD Expands Testing Capabilities to Help Clinicians Improve Diagnostic Accuracy and Efficiency

The BD Vacutainer® Urine Complete Cup Kit preserves specimen quality, streamlines testing, and helps reduce repeat collections to support better patient care FRANKLIN LAKES, N.J., Feb. 23, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD Vacutainer® Urine Complete Cup Kit, a three-tube collection system that expands and supports broader testing capabilities from a single urine specimen.

PRNewsWire • Feb 23, 2026

BD to Present at Barclays 28th Annual Global Healthcare Conference

FRANKLIN LAKES, N.J., Feb. 23, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 8:30 am Eastern Time.

PRNewsWire • Feb 23, 2026

Lanesha Minnix Named General Counsel for BD

FRANKLIN LAKES, N.J., Feb. 19, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Lanesha Minnix has been named executive vice president and general counsel for the company, effective March 16.

PRNewsWire • Feb 19, 2026

BD Merges Biosciences & Diagnostics Business With Waters

BDX completes its Biosciences & Diagnostic spin-off and Waters merger, securing $4B in proceeds as it pivots to a pure-play MedTech focus.

Zacks Investment Research • Feb 11, 2026

Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities

FRANKLIN LAKES, N.J., Feb. 10, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) (the "Company" or "BD"), a leading global medical technology company, today announced that it has commenced tender offers to purchase for cash the debt securities issued by the Company listed in the table below (collectively, the "Securities" and each a "series").

PRNewsWire • Feb 10, 2026

Becton, Dickinson and Company: A Q1 2026 Earnings And Post Spin-Off Examination

Becton, Dickinson and Company delivered a Q1 2026 earnings beat, with $2.91 Non-GAAP EPS and $5.25B revenue, surpassing expectations. BDX completed the spin-off of its Life Sciences & Diagnostic Solutions segment, receiving $4B to be split between debt reduction and share repurchases. Management reaffirmed FY26 guidance, projecting low single-digit revenue growth and established adjusted EPS of $12.35–$12.65, implying ~6% growth at midpoint.

Seeking Alpha • Feb 10, 2026

What's Going On With Becton Dickinson Stock Tuesday?

The company reported sales of $5.25 billion, slightly above the consensus of $5.15 billion.

Benzinga • Feb 10, 2026

Becton Dickinson cuts annual profit forecast to reflect sale of biosciences and diagnostics unit

Medical device maker Becton Dickinson cut its profit forecast for fiscal year 2026 on Monday, adjusting its outlook to account for the separation and sale of its biosciences and diagnostics unit to lab equipment manufacturer Waters.

Reuters • Feb 9, 2026

Becton, Dickinson and Company (BDX) Q1 2026 Earnings Call Transcript

Becton, Dickinson and Company (BDX) Q1 2026 Earnings Call Transcript

Seeking Alpha • Feb 9, 2026